细胞外基质
纤维化
药物输送
透皮
瘢痕疙瘩
增生性瘢痕
曲安奈德
癌症研究
细胞外
成纤维细胞
药理学
医学
药品
化学
糖皮质激素
细胞生物学
机制(生物学)
作用机理
颠倒
人体皮肤
伤口愈合
联合疗法
抗药性
模式治疗法
基质(化学分析)
真皮
生物医学工程
肌成纤维细胞
托法替尼
作者
Yifei Lu,Peng Yang,Weiming Gou,Yangping Wang,Li Ran,Lin Shi,Yiming Qin,Jingyuan Li,Ning Zhang,Dongdong Xue,Ming Ao,Zhan Shu,Xingyue Zhang,Yaqin Zhou,Ling Huang,Dengfeng He,Xiaorong Zhang,Yong Huang,Haisheng Li,Junyi Zhou
标识
DOI:10.1016/j.xcrm.2026.102592
摘要
Challenges and opportunities in multimodal synergistic therapy for skin fibrosis encompass elucidating the mechanisms of synergistic treatment, optimizing and developing highly coupled combinations, and eliminating therapeutic resistance. This study reveals that the excessively deposited extracellular matrix of hypertrophic scar not only forms a physical barrier for local drug delivery but also generates high mechanical stress, which drives glucocorticoid insensitivity by activating the FAK-AKT-HDAC2 axis in fibroblasts. Both mechanical and biological barriers result in poor outcomes of triamcinolone acetonide therapy for hypertrophic scars. To address this, a chemomechanical antifibrotic approach is engineered by integrating a microneedle-based transdermal delivery platform, immobilized enzymes, and long-acting sustained-release microspheres. This strategy significantly sensitizes scar fibroblasts by disrupting the fibrotic extracellular matrix and the resultant mechanics-induced cellular programs for drug resistance, thus notably reversing the fibrotic characteristics. These findings uncover a mechanism of glucocorticoid resistance and present a multimodal, self-administrable therapy against fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI